Regnum Corp.
RGMP
$0.00
$0.000.00%
OTC PK
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
Filings
Filing Date
Monday, May 15, 2023
Period Date
Friday, March 31, 2023
Next Filing
(est)
Price History
Beta
7-Day Total Return
--
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
--
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
--
Phone Number
877 313 2232
Address
600 Third Avenue
New York, NY 10016
New York, NY 10016
Country
Year Founded
Business Description
Sector
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist...
more